iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

New challenges in therapeutic vaccines against HIV infection

(2017) Lorna Leal et al.   Expert Review of Vaccines

Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes

(2017) Jeffrey Dock et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

(2016) Ruxandra Calin et al.   AIDS

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

(2016) Matthias A. Oberli et al.   NANO LETTERS

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

(2016) Erica N. Borducchi et al.   NATURE

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

(2015) Beatriz Mothe et al.   Journal of Translational Medicine

Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs

(2015) Kevin J. Kauffman et al.   NANO LETTERS

DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift

(2015) Anna L. de Goede et al.   VACCINE

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

(2015) S. Van Lint et al.   Cancer Immunology Research

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

(2014) Sandra Van Lint et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected

(2014) Marta Ruiz-Riol et al.   JOURNAL OF INFECTIOUS DISEASES

Immunologic strategies for HIV-1 remission and eradication

(2014) D. H. Barouch et al.   SCIENCE

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption

(2013) Anna L. de Goede et al.   AIDS

Immune interventions in HIV infection

(2013) Guislaine Carcelain et al.   IMMUNOLOGICAL REVIEWS

High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers

(2013) Olivier Lambotte et al.   PLoS One

A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication

(2013) F. Garcia et al.   Science Translational Medicine

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

(2013) A.-W. Chan et al.   BMJ-British Medical Journal

mRNA

(2013) Sandra Van Lint et al.   Human Vaccines & Immunotherapeutics

CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control

(2012) Beatriz Mothe et al.   PLoS One

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

(2011) Ellen Van Gulck et al.   AIDS

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

(2011) Sabine D. Allard et al.   CLINICAL IMMUNOLOGY

mRNA as gene therapeutic: How to control protein expression

(2010) Geertrui Tavernier et al.   JOURNAL OF CONTROLLED RELEASE

The Challenge of Finding a Cure for HIV Infection

(2009) D. D. Richman et al.   SCIENCE

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

(2008) Aude Bonehill et al.   MOLECULAR THERAPY